21 CFR 606.100
Establish, maintain and follow manufacturing SOPs
- Inspections citing it: 1,703
- Of those classified, ended OAI: 3%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 606.100(b)
- 1,076 · Establish, maintain and follow manufacturing SOPs
- 606.100(c)
- 387 · Thorough investigations
- 606.100(b)(15)
- 60 · Schedules and procedures for equipment & calibration
- 606.100(b)(10)
- 31 · Controlling storage temperatures
- 606.100(b)(14)
- 24 · QC procedures for supplies and reagents
- 606.100(b)(21)
- 23 · Donor notification
- 606.100(b)(1)
- 20 · Donor criteria
- 606.100(b)(9)
- 14 · Written methods for investigating adverse reactions
Regulation Text
eCFR did not answer; open it on eCFRRecently Cited Sites
Newest inspections citing this section; each opens the site- Munson Medical CenterUnited States · Aug 7, 2026
- HCSC-Blood CenterUnited States · Jul 20, 2026
- New York Blood Center, Inc.United States · Jul 17, 2026
- UC Health Poudre Valley HospitalUnited States · Jul 16, 2026
- Biomat USA IncUnited States · Apr 14, 2026
- The Blood Connection - LexingtonUnited States · Jan 13, 2026
- Octapharma Plasma IncUnited States · Dec 11, 2025
- American National Red CrossUnited States · Dec 10, 2025
- BioLife Plasma Services LPUnited States · Dec 5, 2025
- Creative Testing SolutionsUnited States · Aug 29, 2025
- The Blood Connection, IncorporatedUnited States · Jul 16, 2025
- Lifesouth Community Blood Centers - Montgomery RegionUnited States · Apr 14, 2025
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR